Anti-cyclin B1 antibodies have been found to increase in lung cancer [98], with low to moderate prediction potential as individual autoantibody, and oesophageal carcinoma, with high specificity and moderate sensitivity in predicting cancer risk when in a panel with other 7 autoantibodies (p53, IMP1, P16, P62, c-myc, Survivn, and Koc) [99]. Here, MYC is linked to cancer.